Natera Seeks FDA Approval for Signatera CDx in Bladder Cancer Treatment
Event summary
- Natera submitted a premarket approval (PMA) application to the FDA for Signatera™ CDx, aimed at detecting molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC).
- The submission is backed by data from the phase 3 IMvigor011 trial, which showed statistically significant improvements in disease-free and overall survival for Signatera-positive patients treated with atezolizumab.
- IMvigor011 was sponsored by Genentech, a member of the Roche Group, and results were presented at ESMO Congress on October 20, 2025.
The big picture
Natera's submission marks a critical step in advancing personalized treatment for bladder cancer, an area where identifying high-risk patients has been historically challenging. The approval of Signatera CDx could set a precedent for MRD-guided therapies, potentially reshaping how oncology treatments are tailored to individual patient needs.
What we're watching
- Regulatory Approval
- Whether the FDA will approve Signatera CDx, potentially making it the first companion diagnostic MRD test for MIBC.
- Market Adoption
- The pace at which oncologists and healthcare systems integrate MRD-guided treatment into standard care for bladder cancer.
- Competitive Dynamics
- How Natera’s success with Signatera CDx could influence the broader precision oncology diagnostics market.
Related topics